Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PPAR agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: PPAR agonist. Displaying page 1 of 1.
    EudraCT Number: 2005-004216-70 Sponsor Protocol Number: BM17864 Start Date*: 2007-01-30
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003861-34 Sponsor Protocol Number: 0/2004 Start Date*: 2005-06-08
    Sponsor Name:Department of Nuclear Medicine
    Full Title: Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects
    Medical condition: There is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the de...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004296-35 Sponsor Protocol Number: RGHT000203 Start Date*: 2007-10-18
    Sponsor Name:The Royal Group of Hospitals, Belfast Health and Social Care Trust [...]
    1. The Royal Group of Hospitals, Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment
    Medical condition: The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment wit...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000570-52 Sponsor Protocol Number: 1/2005 Start Date*: 2006-03-17
    Sponsor Name:CRC, Medical Department IV, University Erlangen-Nuremberg
    Full Title: Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck
    Medical condition: essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007075-16 Sponsor Protocol Number: GE07-12 Start Date*: 2008-12-01
    Sponsor Name:VU university medical center
    Full Title: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with p...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004112-13 Sponsor Protocol Number: 33100 Start Date*: 2009-06-26
    Sponsor Name:Nottingham University
    Full Title: PPAR-gamma: A noval therapeutic target for asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005747-29 Sponsor Protocol Number: BP20843 Start Date*: 2007-03-14
    Sponsor Name:F. HOFFMANN-LA ROCHE LTD
    Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs
    Medical condition: Primary hypercholesterolemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000671-16 Sponsor Protocol Number: BC28027 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities
    Medical condition: - Stable Cardiovascular Disease and - Diabetes Mellitus Type 2 or Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036481 Pre-diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012270-12 Sponsor Protocol Number: BC22419 Start Date*: 2010-05-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®
    Medical condition: Type 2 diabetes with moderate renal function impairment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001639-29 Sponsor Protocol Number: BC25445 Start Date*: 2012-08-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated type 2...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012269-71 Sponsor Protocol Number: BC22140 Start Date*: 2010-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
    Medical condition: Type 2 diabetes patients with a recent acute coronary syndrome (ACS) event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) DK (Prematurely Ended) FR (Completed) IE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001691-36 Sponsor Protocol Number: 0893-008 Start Date*: 2007-09-07
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-002301-38 Sponsor Protocol Number: AVD111179 Start Date*: 2008-08-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus
    Medical condition: Effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015883-32 Sponsor Protocol Number: 28431754DIA3005 Start Date*: 2010-02-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects Wit...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) ES (Completed) IS (Completed) EE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 00:47:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA